News

Pralatrexate (PDX) is said to be a novel, small molecule chemotherapeutic agent that inhibits dihydrofolate reductase (DHFR), a folic acid (folate)-dependent enzyme involved in the building of nucleic

The randomized, single-blind, controlled, multi-center Phase I clinical trial of the Intercept red blood cell system is expected to enroll approximately 28 healthy subjects. Each subject will receive

Upon approval by the European Commission in early 2009, Valdoxan is expected to be marketed by Servier in European countries in the following months. Data from the company’s

The study is designed to test the efficacy of AEOL 10150 as a treatment for damage to the lungs due to exposure to radiation and to determine the

R&D services will be provided by Chemical Diversity Research Institute, ChemDiv’s research subsidiary based in Moscow. The new agreement provides for research funding of clinical candidate compounds to

Mr Davis, who previously served as the company’s vice president of sales and marketing from May 2007 to February 2008, has more than 20 years experience in the

This marketing approval authorization (MAA) submission will follow the centralized approval procedure with the British Medicines and Healthcare products Regulatory Agency acting as rapporteur and the Italian Agenzia

The Committee for Medicinal Products for Human Use (CHMP) recommends Nplate for adult chronic immune thrombocytopenia purpura (ITP) splenectomised patients who are refractory to other treatments. Nplate may

Dr Kakkis has decided to leave his position with the company to allow him to be able to devote more of his time to personal endeavors related to